Home › Research › Risk factors
Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries
Amir Abbas Tahami Monfared, Raymond J. Zhang, Quanwu Zhang, Ran Gao, Babak Haji. Alzheimer s & Dementia, 2025-12-01
Topic: Risk, prevention and care in population studies
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. Women consisted of 53.1% the infusion group vs 62.2% in the non-infusion group. The infusion group had 91.1% White, 1.1% Black, 0.2% Hispanic, 1% Asian compared to 86% White, 6.7% Black, 1.8 Hispanic, 1.6% Asian in the non-infusion group. Comorbidity rates were generally lower for the infusion vs non-infusion group. Specially, hypertension was 4.5 vs 63%, hyperlipidemia 3.8 vs 47.8%, diabetes 1.7 vs 24.4%, cerebrovascular disease 1.1 vs 14.7%, and congestive heart failure 0.1 vs 11.6% for infusion vs non-infusion group. Among infusion group, 88.7 vs 11.3% were in urban vs rural areas. The states having a higher lecanemab infusion rate include Connecticut (1.9%), Kentucky (1.9%), Massachusetts (1.8%), Wyoming (1.7%), Georgia (1.6%), Missouri (1.4%), California (1.4%), Rhode Island (1.4), Indiana (1.3%), and New Jersey (1.1%). Although lecanemab infusion rate was greater than 1% among only 10 states, the therapy adoption rate among the target population is likely higher as the infusion rate denominator included unconfirmed Alzheimer's cases and patients beyond the early disease stage. Continued medical/scientific education plus availability of home infusion and self-injectable delivery formulation are expected to support increasing lecanemab adoption, especially among minority groups.
Key findings
- Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion.
- Women consisted of 53.1% the infusion group vs 62.2% in the non-infusion group.
- The infusion group had 91.1% White, 1.1% Black, 0.2% Hispanic, 1% Asian compared to 86% White, 6.7% Black, 1.8 Hispanic, 1.6% Asian in the non-infusion group.
- Comorbidity rates were generally lower for the infusion vs non-infusion group.
- Specially, hypertension was 4.5 vs 63%, hyperlipidemia 3.8 vs 47.8%, diabetes 1.7 vs 24.4%, cerebrovascular disease 1.1 vs 14.7%, and congestive heart failure 0.1 vs 11.6% for infusion vs non-infusion group.
Why it matters
Among Medicare beneficiaries, those receiving lecanemab infusions were younger, more likely to be White, and had fewer other illnesses than those not receiving it, and most lived in urban areas. The study describes who is getting this treatment and where, not whether it works.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants2,512
- Effect size53.1%; 62.2%; 91.1%
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,512 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Eisai (United States): institution h-index 251 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41433980) |
| Free to read | 2 / 2 | Free to read |
| Points | 36 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70860_106870
- PubMed: 41433980
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Monfared, A. A. T., Zhang, R. J., Zhang, Q., Gao, R., & Haji, B. (2025). Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries. Alzheimer s & Dementia. https://doi.org/10.1002/alz70860_106870
Vancouver
Monfared AAT, Zhang RJ, Zhang Q, Gao R, Haji B. Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries. Alzheimer s & Dementia. 2025. doi:10.1002/alz70860_106870. PMID: 41433980.
BibTeX
@article{monfared2025-41433980,
author = {Monfared, Amir Abbas Tahami and Zhang, Raymond J. and Zhang, Quanwu and Gao, Ran and Haji, Babak},
title = {{Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70860_106870},
pmid = {41433980},
url = {https://doi.org/10.1002/alz70860_106870}
}